Group 1 - The core point of the article is that Baicheng Pharmaceutical plans to invest 15 million yuan in a private equity fund to enhance asset allocation and improve capital utilization [1] - The investment will be made through Hangzhou Mipeng Enterprise Management Partnership, which is controlled by the company, and the partnership agreement was signed on September 19, 2025 [1] - The investment aligns with the regulations of the Shenzhen Stock Exchange regarding transactions and related party transactions, as the private equity fund is related to the company's main business [1] Group 2 - As of the report, Baicheng Pharmaceutical has a market capitalization of 6.8 billion yuan [2] - For the first half of 2025, the company's revenue composition is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [1]
百诚医药：公司控制的合伙企业拟认购私募基金份额